Derivation and validation of predictors of oral anticoagulant-related adverse events in seniors transitioning from hospital to home

Thromb Res. 2021 Oct:206:18-28. doi: 10.1016/j.thromres.2021.07.016. Epub 2021 Aug 2.

Abstract

Introduction: Oral anticoagulant (OAC)-related adverse events are high post-hospitalization. We planned to develop and validate a prediction model for OAC-related harm within 30 days of hospitalization.

Methods: We undertook a population-based study of adults aged ≥66 years who were discharged from hospital on an OAC from September 2010 to March 2015 in Ontario, Canada. The primary outcome was a composite of time to first hospitalization or emergency department visit for a hemorrhagic or thromboembolic event, or mortality within 30 days of hospital discharge. Cox proportional hazards regression was used to build the model.

Results: We included 120,721 patients of which 5423 experienced the outcome. Most patients were aged ≥75 years (59.5%) and were female (55.6%). Sixty percent of the cohort had a follow-up visit with a healthcare provider within 7 days of discharge. Patients discharged on a direct acting OAC versus warfarin (apixaban: Hazard Ratio [HR] 0.82, 95% confidence interval [CI] 0.71-0.94; dabigatran: HR 0.73, 95% CI 0.63-0.84; rivaroxaban: HR 0.79, 95% CI 0.71-0.88), were prevalent users of the dispensed OAC versus incident users (HR 0.82, 95% CI 0.69-0.96), had a joint replacement in the past 35 days (HR 0.40, 95% CI 0.33-0.50) or major surgery during index hospital stay (HR 0.69, 95% CI 0.60-0.80) had a lower risk for the outcome. The Cox model was stable with acceptable discrimination but poor goodness-of-fit.

Conclusions: A model for OAC-related harm in the early post-discharge period was developed. External validation studies are required to understand the model's poor calibration.

Keywords: Anticoagulants; Continuity of patient care; Drug-related side effects and adverse reactions; Health services research; Statistics.

MeSH terms

  • Administration, Oral
  • Adult
  • Aftercare*
  • Anticoagulants / adverse effects
  • Atrial Fibrillation* / drug therapy
  • Dabigatran / therapeutic use
  • Female
  • Hospitals
  • Humans
  • Ontario / epidemiology
  • Patient Discharge
  • Pyridones / therapeutic use
  • Retrospective Studies
  • Rivaroxaban / therapeutic use

Substances

  • Anticoagulants
  • Pyridones
  • Rivaroxaban
  • Dabigatran